Fast, life-saving tests for small labs
Finnish firm Mobidiag has received a EUR 15-million loan extended by the InnovFin Infectious Diseases Finance Facility under the EU's Horizon 2020 programme. Provided by the European Investment Bank, the loan is accelerating the development of fast, life-saving tests for small laboratories.
© romaset #189997513, 2019 source: stock.adobe.com
Mobidiag, a molecular diagnostics company, has been developing systems to advance the diagnosis of infectious diseases for laboratories of all sizes since 2008. It is headquartered in Espoo, Finland, and has a subsidiary in Paris.
The firms Amplidiag family of tests enables large laboratories to detect gastrointestinal infections and antibiotic resistance.
Amplidiag is a great success in Nordic countries, where we have closed long-term agreements with large private and public laboratories. We are now moving into France and the UK, says Mobidiag CEO Tuomas Tenkanen.
Mobidiags Novodiag range, which is being finalised, manufactured, validated and commercialised using the loan, offers automated, on-demand solutions for small laboratories. It is particularly useful in cases where immediate detection of infectious diseases is crucial.
Amplidiag is a platform that can run up to 48 stool samples and provide results after two and a half hours, says Tenkanen.
For Novodiag, the time will be reduced to one hour, he adds.
Like Amplidiag, Novodiag tackles antibiotic resistance. It does this by identifying resistance to two widely used types of antibiotics: carbapenem and colistin. Its ease of use minimises risks from human error or fatigue, thereby ensuring accuracy and consistency.
A tired laboratory technician at 3 a.m. can run these tests just by following some simple steps that take a few minutes, says Tenkanen.
Mobidiag is the third recipient of a loan through the InnovFin Infectious Diseases Finance Facility.
For Tenkanen, InnovFin is valuable in a variety of different ways.
Firstly, it fills a gap for companies developing new products as when you get to the commercialisation stage there arent many funding sources out there, he says. Secondly, the process for obtaining the funding is so thorough that afterwards it becomes much easier to find further financing elsewhere. This has certainly been our experience.